Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026
New Cancer Vaccine is Promising in Preclinical Research
/in Immunotherapy, Preclinical Research/by MaxAMPLITUDE: a Phase 3 Clinical Trial of Niraparib Combined with Abiraterone Acetate for HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxScientists Develop “Velcro” Cancer Treatment That Works Across Many Tumor Types
/in Immunotherapy, Preclinical Research/by MaxResearchers at the University of California, Irvine have developed an innovative cancer immunotherapy called GlyTR, a new class of treatment that uses a “velcro-like” mechanism to target sugar molecules abundantly present on cancer cells. Their findings were published in September 2025 in the prestigious journal Cell, marking a significant advancement in cancer immunotherapy. Traditional immunotherapies […]
New Study Uncovers Mechanism Behind T-Cell Exhaustion, Offering Hope for Prostate Cancer Immunotherapy
/in Immunotherapy, Preclinical Research/by MaxA study from The Ohio State University Comprehensive Cancer Center has illuminated a critical reason why cancer immunotherapy often fails: T-cell exhaustion driven by a novel stress pathway called TexPSR (proteotoxic stress response in T-cell exhaustion). Published in the prestigious journal Nature, this discovery reveals a proteotoxic shock in exhausted T cells caused by the […]
Phase 2 Trial Compares Cabazitaxel and ARPIs in Poor-Prognosis mCRPC After Docetaxel
/in Clinical Trial, Metastatic, Phase 2/by MaxLUNAR Trial Shows Combination Therapy Doubles Progression-Free Survival in Recurrent Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxASPIRE Trial Explores Early Chemotherapy Addition for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: 161Tb-PSMA Offers Hope After Lutetium Failure in mCRPC
/in Clinical Trial, Metastatic/by Max